ARVO 2017 to showcase latest advances in treatments for eye disease and blindness

Download PDF Copy

Reviewed

May 2 2017

WHEN
Monday, May 8, 9:30 – 10:15 am Eastern DST (GMT -4)

WHAT
The Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) is the largest gathering of eye and vision researchers in the world, with over 11,000 attendees from more than 75 countries. This Meeting showcases cutting-edge eye and vision science and an early glimpse into the latest advances in potential treatments for eye disease and blindness.

FEATURING
Three researchers will share their latest results, including:

Who will get AMD? Teaching algorithms to predict who's at risk

A machine learning algorithm, using images of patients' retinas obtained over time, can predict the critical moment when early or intermediate age-related macular degeneration (AMD) will progress into severe AMD.

Presenter: Hrvoje Bogunovic, PhD (Medical University of Vienna), works with Ursula Schmidt-Erfurth, MD, on medical image analysis and machine learning with applications in healthcare.

Restoring vision: New hope for retinal cell replacement

Scientists have learned to grow enough specialized neurons that relay visual data to the brain to create a source of cells for future treatments of glaucoma and other optic neurodegenerative diseases.

Presenter: Julia Oswald, PhD (Schepens Eye Research Institute, Harvard Medical School), works in the lab of Petr Baranov, MD, PhD, where she is working toward a cure for glaucoma with stem cell replacement therapies for the eye.

Prenatal marijuana use: Potential long-term effects on babies' eyes

Scientists have shown for the first time that gestational exposure to marijuana smoke in animals affects the development of the eye and these alterations seem to progress with age.

Presenter: Paulo Zantut, MD (University of Sao Paulo, Brazil), is a PhD candidate and a member of the lab of Francisco Max Damico, MD, PhD, which studies retinal and ocular drug toxicity.

The researchers and their principal investigators will be available for interview.

WHERE